Clarification needed for pembrolizumab as adjuvant therapy in clear cell renal cell carcinoma

Tomer Meirson; Victoria Neiman; Michal Sternschuss; Gal Markel; Ian F. Tannock

doi:10.1016/S1470-2045(22)00629-5

Clarification needed for pembrolizumab as adjuvant therapy in clear cell renal cell carcinoma

Tomer Meirson
, Victoria Neiman
, Michal Sternschuss
, Gal Markel
, Ian F. Tannock

Clinical Microbiology and Immunology

Rabin Medical Center Israel
Princess Margaret Hospital

Research output: Contribution to journal › Letter › peer-review

7 Scopus citations

Original language	English
Pages (from-to)	e489
Journal	The Lancet Oncology
Volume	23
Issue number	11
DOIs	https://doi.org/10.1016/S1470-2045(22)00629-5
State	Published - Nov 2022

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1016/S1470-2045(22)00629-5

Cite this

@article{3da5ac4b78d54262a063e96f3e9c507e,

title = "Clarification needed for pembrolizumab as adjuvant therapy in clear cell renal cell carcinoma",

author = "Tomer Meirson and Victoria Neiman and Michal Sternschuss and Gal Markel and Tannock, \{Ian F.\}",

year = "2022",

month = nov,

doi = "10.1016/S1470-2045(22)00629-5",

language = "אנגלית",

volume = "23",

pages = "e489",

journal = "The Lancet Oncology",

issn = "1470-2045",

publisher = "Elsevier Ltd.",

number = "11",

}

TY - JOUR

T1 - Clarification needed for pembrolizumab as adjuvant therapy in clear cell renal cell carcinoma

AU - Meirson, Tomer

AU - Neiman, Victoria

AU - Sternschuss, Michal

AU - Markel, Gal

AU - Tannock, Ian F.

PY - 2022/11

Y1 - 2022/11

UR - https://www.scopus.com/pages/publications/85141286712

U2 - 10.1016/S1470-2045(22)00629-5

DO - 10.1016/S1470-2045(22)00629-5

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.letter???

C2 - 36328018

AN - SCOPUS:85141286712

SN - 1470-2045

VL - 23

SP - e489

JO - The Lancet Oncology

JF - The Lancet Oncology

IS - 11

ER -

Clarification needed for pembrolizumab as adjuvant therapy in clear cell renal cell carcinoma

UN SDGs

Access to Document

Other files and links

Cite this